BioSpace News Archive

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the enrollment of the 36th patient in the ENVASARC pivotal trial at the 600 mg dose of envafolimab, which enables the initial independent data monitoring committee (IDMC) interim efficacy analysis to proceed.

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it entered into a $60 million unsecured line of credit facility with its chairman and largest individual stockholder, Richard E. Uihlein.

Alimera Sciences, Inc. announced that the PALADIN Phase 4 Study confirms the safety of ILUVIEN® 0.19 mg sustained release intravitreal implant and provides a durable treatment option that reduces the frequency of recurrence for patients with diabetic macular edema.

Spectral Medical Inc. today announced that Dr. John Kellum, Spectral’s Chief Medical Officer, will be the featured speaker in a webinar hosted by Sepsis Alliance during Sepsis Awareness Month.

STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, announced today it has been awarded a Small Business Innovation Research (SBIR) grant for approximately $2,100,000 from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).

Companies aim to support development of up to 15 new genomic medicine products.

GEn1E plans to use the novel discovery, which is licensed from University of Maryland, Baltimore to develop therapies for pulmonary, oncology and muscle degenerative diseases.

BioCare, Inc., a leading specialty pharmaceutical distribution partner that provides distribution, specialty pharmacy and logistics services, today announced the expansion of its leadership team with the addition of Tom Hart.

Company to Distribute Recent FDA-Approved Treatment for Reducing Bad Cholesterol.

Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents in Japan.